Breast Cancer Survivors At Higher Risk Of Recurrence With Use Of Synthetic Steroid

News — By on February 19, 2009 at 1:00 am

An article in The Lancet Oncology’s February issue reports that a breast cancer patient´s risk of recurrence increases considerably with the use of Tibolone, a synthetic steroid used in preventing osteoporosis and treating menopausal symptoms. As a result, breast cancer survivors and current patients should not be givenTibolone. Early menopause is frequently a result of breast cancer treatments, such as chemotherapy.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback